PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 18930254-8 2008 While not often reported as an end point, a significant increase in prostate specific antigen doubling time was observed in a study on lycopene supplementation. Lycopene 135-143 kallikrein related peptidase 3 Homo sapiens 68-93 21335507-7 2011 In the placebo arm, a 10 mug/dL increase in lycopene was associated with a 7% (95% CI: 14-0) reduced risk of cancer diagnosed following an elevated PSA or abnormal DRE, which are cancers that best match those detected in screened populations. Lycopene 44-52 kallikrein related peptidase 3 Homo sapiens 148-151 20819671-0 2010 Effect of lycopene on androgen receptor and prostate-specific antigen velocity. Lycopene 10-18 kallikrein related peptidase 3 Homo sapiens 44-69 20819671-7 2010 The phase II pilot study patients (n=41) previously diagnosed with prostate cancer were enrolled and given lycopene supplement, 10 mg per day, and response was measured by observing changes in the plasma prostate-specific antigen (PSA) levels. Lycopene 107-115 kallikrein related peptidase 3 Homo sapiens 204-235 18930254-7 2008 A significant decrease in prostate specific antigen was observed in some studies using a low fat vegan diet, soy beverage or lycopene supplement. Lycopene 125-133 kallikrein related peptidase 3 Homo sapiens 26-51 18156403-7 2008 The 6-mo lycopene supplementation decreased PSA levels in men (P < 0.05), whereas there was no change in the placebo group. Lycopene 9-17 kallikrein related peptidase 3 Homo sapiens 44-47 16301113-7 2005 RESULTS: Our results show that lycopene can delay or prevent HGPIN from developing into occult prostate cancer, and there exists an inverse relationship between lycopene and prostate-specific antigen. Lycopene 161-169 kallikrein related peptidase 3 Homo sapiens 174-199 17927495-4 2007 In this Phase II clinical trial, we investigated the efficacy of lycopene alone or in combination with soy isoflavones on serum PSA levels in men with prostate cancer. Lycopene 65-73 kallikrein related peptidase 3 Homo sapiens 128-131 17927495-11 2007 The data suggest that lycopene and soy isoflavones have activity in prostate cancer patients with PSA relapse disease and may delay progression of both hormone-refractory and hormone-sensitive prostate cancer. Lycopene 22-30 kallikrein related peptidase 3 Homo sapiens 98-101 16906286-8 2006 Dietary ingestion of 50 g of tomato paste per day for 10 weeks significantly reduced mean plasma PSA levels in patients with benign prostate hyperplasia, probably as a result of the high amount of lycopene in tomato paste. Lycopene 197-205 kallikrein related peptidase 3 Homo sapiens 97-100 17571945-1 2007 This unblinded, randomized, Phase I clinical trial was conducted to determine whether lycopene supplementation lowered serum prostate specific antigen (PSA), surrogate endpoint for prostate cancer initiation or progression, in men with elevated prostate cancer risk. Lycopene 86-94 kallikrein related peptidase 3 Homo sapiens 125-150 17571945-1 2007 This unblinded, randomized, Phase I clinical trial was conducted to determine whether lycopene supplementation lowered serum prostate specific antigen (PSA), surrogate endpoint for prostate cancer initiation or progression, in men with elevated prostate cancer risk. Lycopene 86-94 kallikrein related peptidase 3 Homo sapiens 152-155 17571945-9 2007 We conclude that the PSA lowering response to antioxidant supplementation observed in previous 3-wk studies in men awaiting prostatectomy may have been a transient response, perhaps not specific to lycopene. Lycopene 198-206 kallikrein related peptidase 3 Homo sapiens 21-24 17121935-5 2006 Levels of prostate-specific antigen secreted into the incubation medium by LNCaP cells were reduced 55% as a result of lycopene treatment at 1.48 micromol/L. Lycopene 119-127 kallikrein related peptidase 3 Homo sapiens 10-35 16983396-0 2006 Lycopene inhibits DNA synthesis in primary prostate epithelial cells in vitro and its administration is associated with a reduced prostate-specific antigen velocity in a phase II clinical study. Lycopene 0-8 kallikrein related peptidase 3 Homo sapiens 130-155 33355018-1 2021 Several randomized controlled trials (RCTs) have investigated the effect of lycopene supplementation on serum levels of prostate-specific antigen (PSA) in patients with prostate cancer. Lycopene 76-84 kallikrein related peptidase 3 Homo sapiens 120-145 12930422-12 2003 CONCLUSION: Adding lycopene to orchidectomy produced a more reliable and consistent decrease in serum PSA level; it not only shrinks the primary tumour but also diminishes the secondary tumours, providing better relief from bone pain and lower urinary tract symptoms, and improving survival compared with orchidectomy alone. Lycopene 19-27 kallikrein related peptidase 3 Homo sapiens 102-105 33355018-1 2021 Several randomized controlled trials (RCTs) have investigated the effect of lycopene supplementation on serum levels of prostate-specific antigen (PSA) in patients with prostate cancer. Lycopene 76-84 kallikrein related peptidase 3 Homo sapiens 147-150 33355018-3 2021 We systematically searched PubMed, Embase, and Scopus up to January 2020 to find RCTs investigating the effect of lycopene supplementation on serum levels of PSA in patients with non-metastatic prostate cancer. Lycopene 114-122 kallikrein related peptidase 3 Homo sapiens 158-161 33355018-10 2021 Although lycopene supplementation did not produce any reduction in PSA levels overall, a significant reducing effect was observed in patients with higher levels of baseline PSA. Lycopene 9-17 kallikrein related peptidase 3 Homo sapiens 173-176 27406859-2 2017 We tested whether a lycopene-rich tomato intervention could reduce the levels of prostate specific antigen (PSA) in prostate cancer patients. Lycopene 20-28 kallikrein related peptidase 3 Homo sapiens 108-111 27406859-6 2017 In separate post-hoc analyses, we observed that median PSA-values decreased by 1% in patients with the highest increases in plasma lycopene, selenium and C20:5 n-3 fatty acid, compared to an 8.5% increase in the patients with the lowest increase in lycopene, selenium and C20:5 n-3 fatty acid (p = 0.003). Lycopene 131-139 kallikrein related peptidase 3 Homo sapiens 55-58 27406859-6 2017 In separate post-hoc analyses, we observed that median PSA-values decreased by 1% in patients with the highest increases in plasma lycopene, selenium and C20:5 n-3 fatty acid, compared to an 8.5% increase in the patients with the lowest increase in lycopene, selenium and C20:5 n-3 fatty acid (p = 0.003). Lycopene 249-257 kallikrein related peptidase 3 Homo sapiens 55-58 27406859-7 2017 Also, PSA decreased in patients with the highest increase in lycopene alone (p = 0.009). Lycopene 61-69 kallikrein related peptidase 3 Homo sapiens 6-9 26165176-9 2015 Percent increase in beta-cryptoxanthin, cis-lutein/zeaxanthin and all-trans-lycopene were associated with lower PSA levels at 6 months only. Lycopene 66-84 kallikrein related peptidase 3 Homo sapiens 112-115 24890168-0 2014 Lycopene can reduce prostate-specific antigen velocity in a phase II clinical study in Chinese population. Lycopene 0-8 kallikrein related peptidase 3 Homo sapiens 20-45 24890168-3 2014 We investigated the effect of whole-tomato supplement lycopene on the prostate-specific antigen velocity in selected prostate cancer patients. Lycopene 54-62 kallikrein related peptidase 3 Homo sapiens 70-95 24890168-18 2014 CONCLUSION: Administration of lycopene was able to reduce PSA velocity in this study group. Lycopene 30-38 kallikrein related peptidase 3 Homo sapiens 58-61